American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

R. Donald Harvey conveys his management challenges with patients taking these therapies. Read More ›

Bortezomib/Melphalan/Prednisone (VMP) Followed by Lenalidomide/Dexamethasone (Rd) Overcomes the Poor Prognosis of High-Risk Cytogenetics in Elderly Patients with NDMM

ASH 2015 – Multiple Myeloma

Researchers examined subset of elderly newly diagnosed myeloma patients from the GEM2010 trial and split the patients into 2 arms determined by their cytogenetic abnormalities (high risk and standard risk). Patients with 1q gains were shown to have similar outcomes to those without q1 gains when treated with bortezomib plus melphalan and prednisone, followed by lenalidomide and dexamethasone. Read More ›

Effect of Nilotinib Treatment Duration on Treatment-Free Remission in CP-CML Patients Previously Treated with Imatinib: Interim Results of the ENESTPath Phase 3 Trial

ASH 2015 – Leukemia

ASH 2015 – Multiple Myeloma

Researchers demonstrated that any reduction of dose intensity from 1.3 mg/m2 of bortezomib as a first-line treatment for untreated multiple myeloma patients is associated with inferior OS. Furthermore, it was suggested that the cumulative bortezomib dose be ≥20.75 mg for a better OS. Read More ›

Clinical Impact of MRD Monitoring in Elderly Patients with MM

ASH 2015 – Multiple Myeloma

The elderly are an important subgroup within multiple myeloma patients, and it is important to continuously monitor MRD to help balance efficacy and toxicity of treatments. Researchers demonstrated that MRD negativity was associated with significant improved survival regardless of age or cytogenetic risk. Read More ›

Allogeneic SCT After High versus Reduced-Intensity Conditioning in Patients with MDS or AML: Results of a Phase 3 BMT CTN 0901 Trial

ASH 2015 – Leukemia

ASH 2015 – Castleman's Disease, Lymphoma & CLL

ASH 2015 – Multiple Myeloma

Filanesib, a kinesin spindle protein inhibitor, has demonstrated promising clinical activity in patients with multiple myeloma refractory to proteasome inhibitors and immunomodulatory drugs. This new combination demonstrated good tolerability and an increased observed response rate compared with carfilzomib alone. Read More ›

American Society of Hematology (ASH)

Page 37 of 44